EBI3: A Drug Target / Disease Biomarker (G10148)

Target Name: EBI3

NCBI ID: G10148

EBI3

EBI3: A Drug Target / Disease Biomarker

EBI3, short for Enhanced Background Insulin secretion (EBI3), is a protein that is expressed in the pancreas, a gland located behind the stomach that is responsible for producing insulin to regulate blood sugar levels. EBI3 has been identified as a potential drug target or biomarker for several diseases, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD).

EBI3 is a 21-kDa protein that is expressed in the pancreas, and it is involved in insulin secretion. It is a key regulator of insulin secretion in the pancreas, and it has been shown to play a role in the development and progression of several diseases.

One of the key functions of EBI3 is its role in insulin secretion. EBI3 is a critical regulator of the secretion of insulin by the pancreas, and it is shown to play a key role in the regulation of insulin secretion in response to changes in blood sugar levels. EBI3 is expressed in the pancreas and is involved in the production of insulin, which is responsible for regulating blood sugar levels. When blood sugar levels rise, EBI3 is activated and promotes the secretion of insulin to lower blood sugar levels. When blood sugar levels fall, EBI3 is inhibited and prevents the secretion of insulin.

EBI3 is also involved in the regulation of pancreatic secretion, which is the release of enzymes and hormones from the pancreas into the duodenum. EBI3 plays a key role in the regulation of pancreatic secretion by promoting the secretion of enzymes and hormones into the duodenum, while it is inhibited in the case of high blood sugar levels.

In addition to its role in insulin secretion and pancreatic secretion, EBI3 is also involved in the regulation of cellular signaling. It is a potent inhibitor of the androgen-induced increase in cell proliferation and survival, and it is shown to play a key role in the regulation of prostate cancer cell proliferation.

EBI3 is also involved in the regulation of inflammation. It is a potent inhibitor of the pro-inflammatory response and it is shown to play a key role in the regulation of chronic inflammation.

EBI3 is also a potential biomarker for several diseases, including type 2 diabetes, obesity, and NAFLD. It is an attractive target for these diseases because of its involvement in the regulation of insulin secretion, blood sugar levels, and pancreatic secretion, as well as its role in the regulation of cellular signaling and inflammation.

EBI3 is also a potential drug target for several diseases, including type 2 diabetes, obesity, and NAFLD. Its involvement in the regulation of insulin secretion, blood sugar levels, and pancreatic secretion, as well as its role in the regulation of cellular signaling and inflammation, make it an attractive target for these diseases.

In conclusion, EBI3 is a protein that is expressed in the pancreas and is involved in insulin secretion, blood sugar levels, and pancreatic secretion. It is also involved in the regulation of cellular signaling and inflammation. Its potential as a drug target or biomarker for several diseases, including type 2 diabetes, obesity, and NAFLD makes it an attractive target for future research.

Protein Name: Epstein-Barr Virus Induced 3

Functions: Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines

The "EBI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EBI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets